[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639828":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":41,"locations":47,"responsibleParty":62,"collaborators":28,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":28,"enrollmentInfo":76,"targetDuration":28,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":90,"whyStopped":28,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"The First Affiliated Hospital of Zhengzhou University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"rhPro-UK group","EXPERIMENTAL","On Day 1 after randomization, patients will receive intravenous rhPro-UK plus aspirin placebo (300 mg). From day 2 to day 90, patients will receive standard care according to the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke (2023).",[13,14],"Drug: rhPro-UK","Drug: placebo",{"label":16,"type":17,"description":18,"interventionNames":19},"Control group","ACTIVE_COMPARATOR","On Day 1 after randomization, patients will receive rhPro-UK placebo plus oral aspirin (300 mg). From day 2 to day 90, patients will receive standard care according to the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke (2023).",[20,21],"Drug: Aspirin","Drug: Placebo",[23,29,33,37],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","rhPro-UK","rhPro-UK (5 mg\u002Fvial), to maximum of 35mg",[9],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"placebo","Asprin (placebo)",[9],{"type":24,"name":34,"description":35,"armGroupLabels":36,"otherNames":28},"Aspirin","Asprin (300mg)",[16],{"type":24,"name":38,"description":39,"armGroupLabels":40,"otherNames":28},"Placebo","rhPro-UK(placebo)",[16],[42],{"name":43,"role":44,"phone":45,"phoneExt":28,"email":46},"Bo Song, MD","CONTACT","+86-371-66278068","fccsongb@zzu.edu.cn",[48],{"facility":49,"status":28,"city":50,"state":51,"zip":28,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Department of Neurology, the First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan","China","CN",{"type":55,"coordinates":56},"Point",[57,58],113.64861,34.75778,{"lat":58,"lon":57},[61],{"name":43,"role":44,"phone":45,"phoneExt":28,"email":46},{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"PRINCIPAL_INVESTIGATOR","Bo Song","chief physician、Professor","100639828","phase-3-pro-urokinase-for-extended-window-posterior-circulation-stroke-100639828",false,"NCT07617870","Pro-urokinase for Extended-Window Posterior Circulation Stroke","Pro-urokinase for Reperfusion in Acute pOsterior Circulation ischeMIc Stroke in the Extended Window (the PROMISE Trail): A Randomized, Double-blind, Baseline Treatment-controlled Study","PROMISE","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. AIS with symptom onset 4.5-9 hours before enrollment, including wake-up stroke and unwitnessed stroke (onset time defined as when symptoms were first noticed);\n3. Imaging criteria:\n\n   1. DWI-FLAIR mismatch: visible lesion on DWI with no marked visible lesion on FLAIR;\n   2. DWI infarct core not exceeding one-third of the middle cerebral artery territory, one-half of the anterior cerebral artery territory, or one-half of the posterior cerebral artery territory;\n4. NIHSS score 4-25;\n5. First-ever stroke or previous stroke without significant disability (pre-stroke mRS ≤ 1);\n6. Signed informed consent from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Planned endovascular treatment;\n2. Contradictory to MRI examination;\n3. MRI image not qualified for evaluation;\n4. Serious neurological deficits before onset (mRS≥2);\n5. Obvious head injuries or strokes within 3 months;\n6. Subarachnoid or intracranial hemorrhage;\n7. History of intracranial hemorrhage;\n8. Intracranial tumor, arteriovenous malformation or aneurysm;\n9. Intracranial or spinal cord surgery within 3 months;\n10. Active internal hemorrhage;\n11. platelet count of \\\u003C100000\u002Fmm3;\n12. Aortic arch dissection;\n13. Heparin therapy within 24 hours;\n14. Oral warfarin is being taken and INR\\>1.6 or APTT abnormal;\n15. Oral anticoagulation therapy;\n16. Systolic pressure≥185 mmHg or diastolic pressure≥110 mmHg;\n17. Blood glucose \\\u003C 50 mg\u002Fdl (2.7mmol\u002FL);\n18. Pregnancy;\n19. Neurological deficit after epileptic seizures;\n20. Major surgery within 1 month;\n21. Gastrointestinal or urinary tract hemorrhage within the previous 30 days;\n22. Myocardial infarction within 3 months;\n23. Allergy to study drugs;\n24. Unlikely to adhere to the trial protocol or follow-up;\n25. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;\n26. Participation in other interventional clinical trials within the previous 3 months.","ALL","18 Years",{"count":77,"type":78},586,"ESTIMATED","INTERVENTIONAL",[81],"PHASE3","This study aims to evaluate whether, in patients with imaging-confirmed acute ischemic stroke of the posterior circulation presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy, intravenous thrombolysis with recombinant human prourokinase (rhPro-UK), compared with standard medical treatment, can achieve superior 90-day functional outcomes with a higher level of safety.",[84],"Acute Ischemic Stroke",[86,87,88,89],"Recombinant human prourokinase (rhPro-UK)","Posterior circulation ischemic stroke","Extended-window thrombolysis","Intravenous thrombolytic therapy","NOT_YET_RECRUITING","2026-05-26",{"date":93,"type":94},"2026-06-01","ACTUAL",{"date":93,"type":78},{"date":97,"type":78},"2028-06-30",{"name":5,"class":6},1]